| BCG | An attenuated strain of Mycobacterium bovis used in the preparation of BCG vaccine that is used for immunization against tuberculosis and in cancer chemotherapy. Extracts of the bacterium have remarkable powers in stimulation of lymphocytes and leucocytes and are used in adjuvants. Synonym: Calmette-Guerin bacillus. Acronym: BCG Origin: Fr. (05 Mar 2000) |
|---|---|
| BCG vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| BcgI methyltransferase | <enzyme> From bacillus coagulans; an m(6)a-methyltransferase which produces n-6 methyladenine as the sole product of bcgi methylation Registry number: EC 2.1.1.- Synonym: bcgi methylase (26 Jun 1999) |
| bcl | <oncogene> Two variants of this oncogene are recognised. 1. Bcl-2: A proto-oncogene, activated by chromosome translocation in human B-cell lymphomas (hence bcl). Encodes a plasma membrane protein. The gene product inhibits programmed cell death (apoptosis) and is homologous with the worm gene ced 9. See: ced mutant. 2. Bcl-3: An oncogene associated with some cases of B-cell chronic lymphocytic leukaemias. The protein product contains seven ankyrin repeats very similar to those found in I kappa B. Seems to interfere with binding of 50 kD subunit of NF kappa B to DNA. (24 Mar 1998) |
| bcl-2 | <oncogene> Two variants of this oncogene are recognised. 1. Bcl-2: A proto-oncogene, activated by chromosome translocation in human B-cell lymphomas (hence bcl). Encodes a plasma membrane protein. The gene product inhibits programmed cell death (apoptosis) and is homologous with the worm gene ced 9. See: ced mutant. 2. Bcl-3: An oncogene associated with some cases of B-cell chronic lymphocytic leukaemias. The protein product contains seven ankyrin repeats very similar to those found in I kappa B. Seems to interfere with binding of 50 kD subunit of NF kappa B to DNA. (24 Mar 1998) |
| bcl-3 | <oncogene> Two variants of this oncogene are recognised. 1. Bcl-2: A proto-oncogene, activated by chromosome translocation in human B-cell lymphomas (hence bcl). Encodes a plasma membrane protein. The gene product inhibits programmed cell death (apoptosis) and is homologous with the worm gene ced 9. See: ced mutant. 2. Bcl-3: An oncogene associated with some cases of B-cell chronic lymphocytic leukaemias. The protein product contains seven ankyrin repeats very similar to those found in I kappa B. Seems to interfere with binding of 50 kD subunit of NF kappa B to DNA. (24 Mar 1998) |
| BCNU | <chemical> A cell-cycle phase non-specific alkylating antineoplastic agent. It is used in the treatment of brain tumours and various other malignant neoplasms. This substance may reasonably be anticipated to be a carcinogen according to the fourth annual report on carcinogens (ntp 85-002, 1985). Pharmacological action: antineoplastic agent, alkylating, carcinogens. Chemical name: Urea, N,N'-bis(2-chloroethyl)-N-nitroso- (12 Dec 1998) |
| BCR | A region on chromosome 22 that is involved in the Philadelphia translocation. Acronym: BCR (15 Nov 1997) |